Skip to main content

New Selenium-based Targeted Nanocapsules to treat Breast Cancer

Objetivo

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting
for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the
focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women,
causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer
cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for
successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased
therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer
treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic
window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable
NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se
compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer
cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after
chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover,
targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

Ámbito científico

  • /ciencias médicas y de la salud/medicina clínica/cirugía
  • /ciencias naturales/ciencias biológicas/biología celular
  • /ciencias médicas y de la salud/medicina clínica/oncología/cáncer/cáncer de mama
  • /ciencias naturales/ciencias químicas/química inorgánica/compuestos inorgánicos

Convocatoria de propuestas

H2020-MSCA-RISE-2017
Consulte otros proyectos de esta convocatoria

Régimen de financiación

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

Coordinador

UNIVERSIDAD AUTONOMA DE BARCELONA
Dirección
Calle Campus Universitario Sn Cerdanyola V
08290 Cerdanyola Del Valles
España
Tipo de actividad
Higher or Secondary Education Establishments
Aportación de la UE
€ 202 500

Participantes (7)

KAROLINSKA INSTITUTET
Suecia
Aportación de la UE
€ 175 500
Dirección
Nobels Vag 5
17177 Stockholm
Tipo de actividad
Higher or Secondary Education Establishments
ACIB GMBH
Austria
Aportación de la UE
€ 27 000
Dirección
Krenngasse 37/2
8010 Graz
Tipo de actividad
Research Organisations
AB BCN SL

La participación finalizó

España
Aportación de la UE
€ 22 500
Dirección
Lg Bellaterra Parc De Recerca Uab Campus Uni Uab
08193 Cerdanyola Del Valles
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
QUALIZYME DIAGNOSTICS GMBH & CO KG

La participación finalizó

Austria
Aportación de la UE
€ 0
Dirección
Neue Stiftingtalstrasse 2
8010 Graz
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
REGION STOCKHOLM
Suecia
Aportación de la UE
€ 27 000
Dirección
Hantverkargatan 45
104 22 Stockholm
Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH
Austria
Aportación de la UE
€ 27 000
Dirección
Innrain 66A
6020 Innsbruck
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CLINISCIENCES SL
España
Aportación de la UE
€ 22 500
Dirección
Cl Alt De Gironella 67
08017 Barcelona
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)